Sudeep Pharma IPO
Bookbuilding IPO | ₹895.00 Cr | Listing at BSE, NSE
IPO Open
Fri, Nov 21, 2025
IPO Close
Tue, Nov 25, 2025
Price Band
₹563.00 to ₹593.00
Market Cap (Pre-IPO)
₹6,697.85 Cr
IPO Details
| IPO Date | Nov 21, 2025 to Nov 25, 2025 |
| Listing Date | Tentative: Nov 28, 2025 |
| Face Value | ₹1.00 per share |
| Price Band | ₹563.00 to ₹593.00 |
| Lot Size | 25 Shares (Minimum: ₹14,825.00) |
| Sale Type | Offer For Sale + Fresh Issue |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Issue Size | ₹895.00 Crores |
| Total Shares Offered | 15,092,749 shares |
| Fresh Issue | 1,602,023 shares |
| Offer For Sale | 13,490,726 shares |
Sudeep Pharma IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | 75,46,373 (50.00%) |
| Retail Shares Offered | 52,82,463 (35.00%) |
| NII Shares Offered | 22,63,913 (15.00%) |
Sudeep Pharma IPO Lot Size
Investors can bid for a minimum of 25 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 25 | ₹14,825 |
| Retail (Max) | 13 | 325 | ₹192,725 |
| S-HNI (Min) | 14 | 350 | ₹207,550 |
| S-HNI (Max) | 67 | 1,675 | ₹993,275 |
| B-HNI (Min) | 68 | 1,700 | ₹1,008,100 |
Sudeep Pharma Financial Information (Restated Consolidated)
Sudeep Pharma Ltd.'s revenue increased by 10% and profit after tax (PAT) rose by 4% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 922.26 | 717.17 | 513.87 | 420.11 |
| Total Income | 130.08 | 511.33 | 465.38 | 438.26 |
| Profit After Tax | 31.27 | 138.69 | 133.15 | 62.32 |
| EBITDA | 48.57 | 199.28 | 187.76 | 98.64 |
| NET Worth | 688.32 | 497.53 | 359.07 | 226.29 |
| Reserves and Surplus | 668.52 | 481.11 | 354.59 | 221.88 |
| Total Borrowing | 135.97 | 135.25 | 75.03 | 82.26 |
Amount in ₹ Cr
Key Performance Indicators
As of Monday, March 31, 2025| KPI | Values |
|---|---|
| Debt/Equity | 0.20 |
| RoNW (Return on Net Worth) | 27.88% |
| PAT Margin (Profit After Tax Margin) | 27.63% |
| EBITDA Margin | 39.70% |
| Price to Book Value | 12.93 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 12.46 | 11.07 |
| P/E (x) | 47.61 | 53.55 |
| Promoter Holding | 89.37% | 76.15% |
Company Promoters
- Sujit Jaysukh Bhayani
- Avani Sujit Bhayani
- Shanil Sujit Bhayani
- Sujeet Jaysukh Bhayani HUF
- Riva Resources Private Limited
- and Bhayani Family Trust are the promoters of the company.
Company Overview
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.
The company operates six manufacturing facilities with a combined production capacity of 50,000 MT, specializing in minerals such as calcium, iron, magnesium, zinc, potassium, and sodium
The company supplies more than 200 products to a diverse customer base across pharma, food, and nutrition sectors
The company has strong R&D capabilities with in-house labs and pilot-scale facilities focused on mineral salts and excipients.
Product Portfolio:
- Pharmaceutical, Food and Nutrition Business
- Specialty Ingredients Business
- Triturates
As of December 31, 2024, the company had 704 permanent employees.
Company Strengths
- Market leadership with a diversified product portfolio in a high barrier industry
- Distinguished global customer base with long-standing relationships with key customers
- Well-equipped and regulatory compliant Manufacturing Facilities
- Strong research and development capabilities
Use of Proceeds
| 1) | Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I | 75.81 |
| 2) | General corporate purposes | 12.67 |
Objectives
The Company Sudeep Pharma IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
Quick Info
| Sector | Pharmaceuticals & Biotechnology |
| Exchange | BSE, NSE |
| Market Cap (Pre-IPO) | ₹6,697.85 Cr |
Important Dates
| IPO Open | Nov 21, 2025 |
| IPO Close | Nov 25, 2025 |
| Allotment Date | Nov 26, 2025 |
| Credit to Demat | Nov 27, 2025 |
| Listing Date | Tentative: Nov 28, 2025 |
Lead Manager(s)
ICICI Securities Ltd.
Registrar
Description
- Sudeep Pharma IPO is a book build issue of ₹895.00 crores. The issue is a combination of fresh issue of 0.16 crore shares aggregating to ₹95.00 crores and offer for sale of 1.35 crore shares aggregating to ₹800.00 crores.
- Sudeep Pharma IPO bidding started from Nov 21, 2025 and ended on Nov 25, 2025. The allotment for Sudeep Pharma IPO was finalized on Nov 26, 2025. Sudeep Pharma IPO will list on BSE, NSE with a tentative listing date fixed as Nov 28, 2025.
- Sudeep Pharma IPO price band is set at ₹593.00 per share . The lot size for an application is 25. The minimum amount of investment required by an retail is ₹14,825 (25 shares) (based on upper price). The lot size investment for sNII is 14 lots (350 shares), amounting to ₹2,07,550, and for bNII, it is 68 lots (1,700 shares), amounting to ₹10,08,100.